HC Wainwright Raises Femasys (NASDAQ:FEMY) Price Target to $15.00

Femasys (NASDAQ:FEMY) had its target price increased by HC Wainwright from $12.00 to $15.00 in a research note released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Femasys Price Performance

Shares of Femasys stock opened at $1.60 on Wednesday. Femasys has a twelve month low of $0.86 and a twelve month high of $1.84. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The company’s 50 day moving average is $1.37 and its 200 day moving average is $1.21. The company has a market cap of $36.64 million, a price-to-earnings ratio of -1.98 and a beta of -2.85.

Hedge Funds Weigh In On Femasys

Institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Femasys during the 4th quarter valued at about $25,000. Jane Street Group LLC purchased a new stake in Femasys during the fourth quarter valued at approximately $30,000. XTX Topco Ltd raised its position in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the period. Citadel Advisors LLC purchased a new position in shares of Femasys during the 4th quarter worth $45,000. Finally, Northern Trust Corp boosted its stake in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares during the last quarter. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.